GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evelo Biosciences Inc (OTCPK:EVLO) » Definitions » Quick Ratio

Evelo Biosciences (Evelo Biosciences) Quick Ratio : 0.48 (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Evelo Biosciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Evelo Biosciences's quick ratio for the quarter that ended in Sep. 2023 was 0.48.

Evelo Biosciences has a quick ratio of 0.48. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Evelo Biosciences's Quick Ratio or its related term are showing as below:

EVLO' s Quick Ratio Range Over the Past 10 Years
Min: 0.2   Med: 6.38   Max: 24.95
Current: 0.48

During the past 7 years, Evelo Biosciences's highest Quick Ratio was 24.95. The lowest was 0.20. And the median was 6.38.

EVLO's Quick Ratio is ranked worse than
89.45% of 1554 companies
in the Biotechnology industry
Industry Median: 3.515 vs EVLO: 0.48

Evelo Biosciences Quick Ratio Historical Data

The historical data trend for Evelo Biosciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evelo Biosciences Quick Ratio Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial 16.42 8.31 3.58 4.09 4.16

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.69 4.16 0.53 0.20 0.48

Competitive Comparison of Evelo Biosciences's Quick Ratio

For the Biotechnology subindustry, Evelo Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evelo Biosciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's Quick Ratio falls into.



Evelo Biosciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Evelo Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(51.573-0)/12.395
=4.16

Evelo Biosciences's Quick Ratio for the quarter that ended in Sep. 2023 is calculated as

Quick Ratio (Q: Sep. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(18.936-0)/39.761
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evelo Biosciences  (OTCPK:EVLO) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Evelo Biosciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Evelo Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evelo Biosciences (Evelo Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
620 Memorial Drive, 5th Floor, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
Executives
Simba Gill director, officer: President & CEO 515 GALVESTON DR, REDWOOD CITY CA 94063
Mark Bodmer officer: See Remarks C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Marella Thorell officer: Chief Financial Officer 1226 CHARTER LANE, AMBLER PA 19002
Duncan Mchale officer: Chief Medical Officer C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Alexander C Reynolds director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Horizon Technology Finance Corp 10 percent owner 312 FARMINGTON AVENUE, FARMINGTON CT 06032
Jeffrey R. Moore director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Stephen J Carriere officer: Principal Accounting Officer
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Lord Ara Darzi director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Tonya Williams director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139